Filing Flows › Lexicon Pharmaceuticals (LXRX) › Q1 2026
Lexicon Pharmaceuticals (LXRX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Lexicon Pharmaceuticals (LXRX) reported revenue of $21.1M for the first quarter 2026 (Q1 2026), up 17-fold from a year earlier and +284% from the quarter before. Operating margin was -4.7%, net loss $1.0M (4.9% of revenue).
Lexicon Pharmaceuticals, Q1 2026: revenue $21.1M (17× year over year), operating margin -4.7%, net loss $1.0M, operating cash flow −$14.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $21.1M | +284% | 17× |
| Operating profit | −$996K | — | — |
| Net earnings | −$1.0M | — | — |
| Operating cash flow | −$14.7M | — | — |
What changed
Revenue was $21.1M in Q1 2026, up 1572% year over year and up 284% from the previous quarter. License was the largest line at 95% of revenue. Product declined 14%.
Operating costs exceeded revenue by $1.0M, an operating margin of -4.7%. Total costs fell 18% while revenue rose 1572%. The fastest-growing cost line was Cost of revenue (+260%). The quarter ended with a net loss of $1.0M, narrower than the previous quarter's $15.5M loss.
Operating cash flow was −$14.7M. Non-cash charges added back $110K of depreciation and amortization and $3.1M of share-based compensation. Working capital and other items used $16.9M.
Questions
What was Lexicon Pharmaceuticals' revenue in the first quarter 2026?
Lexicon Pharmaceuticals (LXRX) reported revenue of $21.1M for the first quarter 2026 (Q1 2026), up 17-fold from a year earlier and +284% from the quarter before.
Was Lexicon Pharmaceuticals profitable in the first quarter 2026?
Operating loss was $996K (-4.7% of revenue) and net loss $1.0M.